Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24040188 | 0.83 | DAO (0.34) | DAOKCNH2GRIN2BFFAR1MPO | |
| SCHEMBL12414784 | 0.82 | DAO (0.39) | DAOKCNH2GRIN2BFFAR1MPO | |
| SCHEMBL256691 | 0.76 | — | — | |
| SCHEMBL10077232 | 0.72 | MEN1 (0.40) | DAOKCNH2GRIN2BFFAR1MPO | |
| SCHEMBL26926613 | 0.71 | DAO (0.38) | DAOKCNH2GRIN2BFFAR1MPO | |
| SCHEMBL24248353 | 0.71 | PDE2A (0.36) | DAOFFAR1SMN1; SMN2GLS | |
| SCHEMBL14554955 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL1193206 | 0.70 | KCNH2 (0.43) | DAOKCNH2GRIN2BMPOSMN1; SMN2 | |
| SCHEMBL17864265 | 0.70 | — | — | |
| SCHEMBL243531 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DAO 550/4885KCNH2 4751/4885GRIN2B 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.